US 10993967
Combinatorial cancer immunotherapy
granted A61KA61K35/28A61K38/20
Quick answer
US patent 10993967 (Combinatorial cancer immunotherapy) held by Senti Biosciences, Inc. expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Senti Biosciences, Inc.
- Grant date
- Tue May 04 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 31
- CPC classes
- A61K, A61K35/28, A61K38/20, A61K38/208, A61K48/005